Stay updated with breaking news from Daptorum Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update New York & London & Paris, April 28, 2023 - Aptorum Group Limited , a... | April 28, 2023
Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today... | April 28, 2023
Aptorum Group Limited (NASDAQ:APM – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 14,900 shares, a growth of 11.2% from the March 15th total of 13,400 shares. Currently, 1.6% of the company’s shares are short sold. Based […]
A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,
URF Holding Group Limited URF Center 566 Middle Huaihai Road, Huangpu District Shanghai China Attn: Chief... | March 27, 2023